邀请Fang Fang出席会议

Fang Fang,CEO of Abimmune Biopharma, Inc., San Diego, U.S.A. She received close to $100M government grants; brought a first-in-class drug (Fludase) from a pure concept to saving over 100 lives (including infants) under the FDA emergency use authorization; received "Scientific American 50" Award. After close to 10 clinical trials, Fludase was granted “Breakthrough and Fast Track” status by the FDA for the indication of Para-Influenza for which no drug or vaccine is available.于2016年3月17-18日受邀参加了2016年皇后镇分子生物学（上海）会议，并以"From a pure concept to a first-in-class live saving drug and more”为题目，发表了精彩的演讲。